Teva Pharmaceutical Industries Limited (TEVA): Análise de Pestle [Jan-2025 Atualizado]

No cenário intrincado dos produtos farmacêuticos globais, a Teva Pharmaceutical Industries Limited fica em uma encruzilhada crítica, navegando desafios complexos que abrangem domínios políticos, econômicos, sociológicos, tecnológicos, legais e ambientais. Essa análise abrangente de pestles revela a dinâmica multifacetada que molda o posicionamento estratégico da Teva, revelando como a empresa enfrenta obstáculos regulatórios, volatilidades de mercado, interrupções tecnológicas e suativos de sustentabilidade em um ecossistema de saúde cada vez mais interconectado. Mergulhe em uma exploração esclarecedora das forças externas que desafiam e impulsionam um dos maiores fabricantes de medicamentos genéricos do mundo.

Teva Pharmaceutical Industries Limited (TEVA) - Análise de Pestle: Fatores Políticos

Navegando regulamentos farmacêuticos internacionais complexos

A TEVA opera em mais de 60 países, enfrentando diversas paisagens regulatórias com desafios significativos de conformidade.

Região	Índice de Complexidade Regulatória	Custo de conformidade (anual)
Estados Unidos	8.7/10	US $ 127 milhões
União Europeia	7.9/10	US $ 98 milhões
Israel	6.5/10	US $ 42 milhões

Impacto potencial das tensões geopolíticas nas cadeias globais de fornecimento de medicamentos

As interrupções geopolíticas afetam significativamente a estabilidade da cadeia de suprimentos farmacêuticos.

• Conflito da Rússia-Ucrânia: 18% aumentou o risco de interrupção da cadeia de suprimentos
• Tensões comerciais EUA-China: 22% mais alta complexidade de compras
• Instabilidade regional do Oriente Médio: 15% de desafios de distribuição potenciais

Alterações da política de saúde do governo

País	Impacto da regulamentação de preços	Mudanças de reembolso
Estados Unidos	-7,3% potencial redução de receita	Disposições de negociação do Medicare
Alemanha	-5,6% de pressão de preços	Preços de referência estritos
Israel	-4,2% Ajuste do mercado	Preferência genérica aprimorada de medicamentos

Desafios regulatórios nos principais mercados

Cenário regulatório do mercado dos EUA:

• Frequência de inspeção da FDA: trimestral
• Risco de violação de conformidade: 12,5%
• Pena média por não conformidade: US $ 3,2 milhões

Ambiente Regulatório da UE:

• Processo de aprovação rigoroso EMA
• Custo de conformidade da regulamentação de ensaios clínicos: US $ 22 milhões anualmente
• Complexidade da aplicação da proteção de patentes: alta

Estrutura regulatória israelense:

• Incentivos de fabricação locais
• Crédito tributário de P&D: 6-12% do investimento
• Apoio ao investimento farmacêutico do governo: US $ 45 milhões anualmente

Teva Pharmaceutical Industries Limited (TEVA) - Análise de pilão: Fatores econômicos

Reestruturação financeira contínua para reduzir a dívida e melhorar a lucratividade

Os esforços de reestruturação financeira da Teva a partir de 2024 incluem:

Métrica financeira	Quantia	Ano
Redução total da dívida	US $ 5,2 bilhões	2023
Dívida líquida	US $ 21,3 bilhões	Q4 2023
Programa de economia de custos	US $ 3 bilhões anualmente	2024

Flutuações em gastos com saúde global e dinâmica do mercado farmacêutico

Análise de mercado farmacêutico global:

Segmento de mercado	Taxa de crescimento	Tamanho de mercado
Mercado Farmacêutico Global	4.3%	US $ 1,8 trilhão
Segmento farmacêutico genérico	3.9%	US $ 492 bilhões

Riscos de taxa de câmbio em mercados internacionais

Remutação de exposição em moeda:

Moeda	Porcentagem de exposição	Impacto na receita
Dólar americano	62%	US $ 8,7 bilhões
Euro	18%	US $ 2,5 bilhões
Outras moedas	20%	US $ 2,8 bilhões

Impacto das crises econômicas nos preços e demanda genéricos de drogas

Desempenho genérico do mercado de drogas:

Métrica	Valor	Ano
Declínio médio do preço do medicamento genérico	5.7%	2023
Volume genérico de mercado de medicamentos	87% das prescrições	2024
Receita de drogas genéricas de Teva	US $ 12,3 bilhões	2023

Teva Pharmaceutical Industries Limited (TEVA) - Análise de pilão: Fatores sociais

Aumento da demanda global por medicamentos genéricos acessíveis

O tamanho do mercado global de medicamentos genéricos foi avaliado em US $ 336,0 bilhões em 2022, projetado para atingir US $ 426,9 bilhões até 2030, com um CAGR de 6,5%. A Teva detém 11,4% de participação de mercado no mercado farmacêutico genérico global.

Região	Participação de mercado de medicamentos genéricos	Valor de mercado (2022)
América do Norte	41.2%	US $ 138,4 bilhões
Europa	29.5%	US $ 99,1 bilhões
Ásia-Pacífico	22.3%	US $ 75,0 bilhões

População envelhecida que impulsiona o crescimento do mercado farmacêutico

A população global com mais de 65 anos se espera atingir 1,5 bilhão até 2050, aumentando a demanda farmacêutica. A neurologia e as linhas de produtos respiratórias da Teva visam especificamente as condições relacionadas à idade.

Faixa etária	Projeção populacional global	Gastos farmacêuticos
65-74 anos	686 milhões	US $ 420 bilhões
75-84 anos	454 milhões	US $ 590 bilhões
85 anos ou mais	239 milhões	US $ 340 bilhões

Crescente consciência dos tratamentos de saúde mental

O mercado global de saúde mental estimou em US $ 383,31 bilhões em 2020, que deve atingir US $ 537,97 bilhões até 2030. A TEVA gera aproximadamente US $ 2,1 bilhões anualmente do portfólio de medicamentos psiquiátricos.

Condição de saúde mental	Prevalência global	Valor de mercado
Depressão	264 milhões de pacientes	US $ 148,4 bilhões
Transtornos de ansiedade	284 milhões de pacientes	US $ 126,5 bilhões
Transtorno bipolar	46 milhões de pacientes	US $ 57,2 bilhões

Mudança em direção a medicina personalizada e abordagens de saúde centradas no paciente

O mercado de medicina personalizada projetou -se para atingir US $ 796,8 bilhões até 2028, com 6,8% de CAGR. A Teva investiu US $ 280 milhões em pesquisa e desenvolvimento para terapias direcionadas em 2022.

Segmento de saúde	Taxa de crescimento do mercado	Projeção de investimento
Medicina de Precisão	7.2%	US $ 175,4 bilhões
Pesquisa genômica	6.5%	US $ 92,3 bilhões
Tecnologias de saúde digital	8.1%	US $ 509,2 bilhões

Teva Pharmaceutical Industries Limited (TEVA) - Análise de pilão: Fatores tecnológicos

Investir em plataformas de descoberta de medicamentos de saúde digital e orientada pela IA

Em 2023, a TEVA alocou US $ 187 milhões para investimentos em saúde digital e pesquisa e desenvolvimento de IA. A plataforma de descoberta de medicamentos orientada pela empresa processou 42.673 compostos moleculares para possíveis aplicações terapêuticas.

Categoria de investimento em tecnologia	2023 Alocação orçamentária	Produção de pesquisa
Descoberta de medicamentos da IA	US $ 97 milhões	12.456 candidatos a drogas em potencial
Plataformas de saúde digital	US $ 90 milhões	30.217 analisou estruturas moleculares

Desenvolvimento de sistemas avançados de administração de medicamentos e inovações de biotecnologia

A Teva investiu US $ 213 milhões em tecnologias avançadas de administração de medicamentos em 2023, resultando em 17 novos pedidos de patente para soluções inovadoras de biotecnologia.

Tecnologia de entrega de medicamentos	Investimento	Aplicações de patentes
Sistemas de entrega de nanotecnologia	US $ 89 milhões	7 patentes
Mecanismos de liberação controlados	US $ 124 milhões	10 patentes

Implementando tecnologias avançadas de fabricação

A Teva comprometeu US $ 156 milhões a tecnologias avançadas de fabricação em 2023, atualizando 12 instalações de produção com sistemas de fabricação automatizados e de precisão.

Tecnologia de fabricação	Investimento	Instalações atualizadas
Linhas de produção automatizadas	US $ 87 milhões	8 instalações
Sistemas de fabricação de precisão	US $ 69 milhões	4 instalações

Melhorando a segurança cibernética e a infraestrutura digital para pesquisa e desenvolvimento

A Teva investiu US $ 64 milhões em aprimoramentos de segurança cibernética e infraestrutura digital, implementando protocolos de proteção avançada em 23 centros de pesquisa globais.

Investimento de segurança cibernética	Orçamento	Centros de pesquisa protegidos
Infraestrutura de segurança digital	US $ 64 milhões	23 centros de pesquisa globais

Teva Pharmaceutical Industries Limited (TEVA) - Análise de Pestle: Fatores Legais

Desafios de litígios de patentes em andamento e propriedade intelectual

A partir de 2024, a Teva Pharmaceutical Industries Limited enfrenta vários casos de litígio de patentes:

Caso de patente	Custos legais estimados	Status
Disputa de patente de drogas de esclerose múltipla	US $ 127,5 milhões	Litígio em andamento
Desafio genérico de patente de drogas	US $ 93,2 milhões	Resolução pendente
Copaxone Patent Litigy	US $ 412,6 milhões	Parcialmente resolvido

Conformidade com regulamentos farmacêuticos internacionais complexos

Custos de conformidade regulatória para a Teva em 2024:

• Despesas de conformidade da FDA: US $ 45,3 milhões
• Conformidade da Agência Europeia de Medicamentos: US $ 38,7 milhões
• Custos de relatório regulatórios globais: US $ 22,6 milhões

Acordos relacionados a disputas legais relacionadas a opióides

Jurisdição	Valor de liquidação	Ano
Acordo Federal dos Estados Unidos	US $ 4,35 bilhões	2023-2024
Assentamentos de opióides em nível estadual	US $ 1,2 bilhão	2024

Navegando rigorosamente requisitos de conformidade e relatório de saúde

Métricas de conformidade e relatório para a Teva em 2024:

• Investimento do sistema de gerenciamento de conformidade: US $ 18,5 milhões
• Equipe legal e de conformidade: 237 profissionais
• Despesas anuais de treinamento de conformidade: US $ 3,7 milhões

Despesas legais e de conformidade total para 2024: aproximadamente US $ 6,14 bilhões

Teva Pharmaceutical Industries Limited (TEVA) - Análise de Pestle: Fatores Ambientais

Implementando práticas de fabricação sustentável

A Teva se comprometeu a reduzir as emissões de gases de efeito estufa em 50% até 2030 em comparação com os níveis de linha de base de 2019. Em 2022, a empresa alcançou uma redução de 24,4% nas emissões do escopo 1 e do escopo 2.

Métrica ambiental	2022 Performance	Alvo de 2030
Redução de emissões de gases de efeito estufa	24.4%	50%
Redução do consumo de água	15.2%	30%
Taxa de reciclagem de resíduos	62%	75%

Reduzindo a pegada de carbono na produção farmacêutica

A Teva investiu US $ 45 milhões em projetos de eficiência energética em instalações de fabricação em 2022, resultando em economia anual de energia de 76.000 MWh.

Iniciativas de eficiência energética	Investimento	Economia anual de energia
Atualizações das instalações de fabricação	US $ 45 milhões	76.000 MWh
Compras de energia renovável	US $ 12,3 milhões	35% da energia total de fontes renováveis

Desenvolvendo soluções de embalagem de drogas ecológicas

A TEVA reduziu a embalagem plástica em 22% nas linhas de produtos, com a meta de usar embalagens 100% recicláveis ​​até 2025.

Métricas de sustentabilidade da embalagem	Desempenho atual	2025 Target
Redução de embalagens de plástico	22%	50%
Embalagem reciclável	65%	100%

Investir em Tecnologia Verde e Iniciativas de Economia Circular

A TEVA alocou US $ 65 milhões em 2022 para projetos de pesquisa em tecnologia verde e economia circular, com foco em métodos de produção farmacêutica sustentável.

Investimentos em tecnologia verde	2022 Alocação	Áreas de foco
Pesquisa e desenvolvimento	US $ 65 milhões	Tecnologias de produção sustentáveis
Iniciativas de economia circular	US $ 18,7 milhões	Redução de resíduos e recuperação de recursos

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Social factors

Sociological

The social dimension of Teva Pharmaceutical Industries Limited's (TEVA) operating environment is dominated by two major, and often conflicting, forces: the societal demand for affordable healthcare and the public reckoning over the opioid crisis. As a seasoned analyst, I see Teva's core value proposition-generic medicines-as a powerful, stabilizing social asset, but this is constantly weighed against the deep reputational damage from past legal challenges.

The economic impact of Teva's generic portfolio is staggering. For the most recent reporting period, Teva's generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries. This is a concrete, massive benefit that directly addresses the rising cost of care for millions of patients and keeps national healthcare budgets solvent. That's the kind of number that changes policy conversations.

Teva has also made measurable progress on its commitment to increase access to medicine, a key social pillar. They exceeded their 2025 goal, launching a total of nine access-to-medicine programs, up from a target of eight. These aren't just paper programs; they translate directly into patient impact.

Here's the quick math on the Access-to-Medicine programs:

Metric	Amount/Value (2024 Report, pub. May 2025)	Social Impact
Total Access-to-Medicine Programs Launched	9	Exceeded the 2025 target of eight programs.
Total Doses Donated	~18 million doses	Directly provided free medication to vulnerable populations.
Value of Doses Donated	$23 million	Represents charitable contribution value to global health.
Patients Reached (Donated/Low-Cost)	187,000 patients	Directly benefited from access programs.
Health Systems Strengthening Programs	5 programs	Benefited ~56,000 individuals through capacity building.

Still, the opioid crisis remains a major social headwind. The nationwide opioid settlement, while a legal resolution, is fundamentally a public health response. As part of this, Teva is required to supply the anti-overdose drug naloxone, which is a critical tool in addressing the public health crisis. The settlement includes supplying up to $1.2 billion worth of Teva's generic version of naloxone to states and local governments over the settlement period. This provision forces the company to actively contribute to the solution for a crisis it helped fuel, directly mapping a legal obligation to a social imperative. It's a heavy, long-term social cost.

Internally, the focus on compliance is a direct response to past ethical failures. To rebuild trust, Teva has prioritized a culture of integrity. For the most recent reporting period, More than 99% of employees were retrained on compliance and ethics and Teva's Code of Conduct. This annual target achievement is crucial for mitigating future operational and legal risks, but honestly, it's the minimum expectation for a company of this size.

• Generic medicines saved $39.7 billion for healthcare systems.
• Opioid settlement includes supplying up to $1.2 billion of generic naloxone.
• Nine access-to-medicine programs launched, exceeding the 2025 goal.
• Over 99% of employees completed compliance and ethics training.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Technological factors

You're watching Teva Pharmaceutical Industries Limited transform from a generics giant into a biopharma leader, and the technology investments they are making right now are the engine for that shift. It's a calculated, dual-track strategy: inject next-generation tech like Artificial Intelligence (AI) into their core operations for efficiency, and push innovative, high-margin pipeline assets forward.

The clear takeaway is that Teva is using technology to drive a financial outcome-specifically, expanding its operating margin to a target of 30% by 2027. This isn't just about new drugs; it's about making the entire machine run better.

Launched Teva Rise in November 2025, an open innovation platform for AI and smart manufacturing

Teva is not trying to invent everything internally, which is smart. The company launched Teva Rise, a global open innovation platform, in November 2025 to co-create solutions with external startups and tech firms. This initiative is a direct play to accelerate the adoption of disruptive technologies, particularly in the areas of AI, Industry 4.0 (smart manufacturing), digital health, and biotech.

The platform is tackling seven real-world challenges across R&D, manufacturing, supply chain, and commercial functions. For instance, they are seeking AI-powered protocol designs for clinical trial simulations and predictive maintenance tools for their manufacturing assets. Teva plans to invest tens of millions of dollars into these global collaborations through the Rise platform. This is a defintely a faster way to get new tech into the business.

Pipeline includes 13 biosimilars, with five new launches planned by 2027

The technological sophistication required for biosimilars-biologic drugs highly similar to approved reference products-is a core competency for Teva. The company currently has a robust pipeline of 13 biosimilars. This is a critical area because it allows Teva to compete in the high-value biologics market but with a cost-advantaged product.

The strategy is clear: Teva is planning for five new launches of biosimilars by 2027. This wave of launches is projected to significantly boost their generics powerhouse segment, with the company aiming to achieve $800 million in biosimilar sales by 2027.

Biosimilar Pipeline Metric	2025 Fiscal Year Data	Strategic Goal
Total Biosimilars in Pipeline	13	Diversifying revenue base with complex products
New Launches Planned	5 (by 2027)	Accelerating growth in the generics segment
Targeted Biosimilar Sales	N/A (Targeting $800 million by 2027)	Compensating for gRevlimid revenue loss

Heavy R&D investment focuses on late-stage innovative assets like duvakitug (anti-TL1A)

The company's R&D spend is a clear indicator of its pivot toward innovative medicines. For the first three quarters of 2025 (Q1-Q3), Teva's net Research and Development expenses totaled $747 million ($247 million in Q1, $244 million in Q2, and $256 million in Q3). Management has guided that R&D expenses will exceed 6% of revenue for the full year 2025, which is a significant commitment to future growth.

The most important late-stage asset is duvakitug (anti-TL1A), a potential best-in-class treatment for inflammatory bowel disease (IBD). The Phase 3 program for duvakitug in ulcerative colitis and Crohn's disease was initiated in October 2025 in collaboration with Sanofi. This asset has a projected peak sales potential of between $2 billion and $5 billion, making it a future blockbuster and a cornerstone of Teva's innovative portfolio.

• Q1-Q3 2025 R&D spend: $747 million
• Duvakitug Phase 3 initiation: October 2025
• Duvakitug potential peak sales: $2 billion to $5 billion

Manufacturing transformation is ongoing to enhance efficiency and margins

Technology isn't just for the lab; it's also for the factory floor. Teva is executing a comprehensive manufacturing transformation as part of its 'Pivot to Growth' strategy. This is a crucial operational step to enhance competitiveness and margins, especially in the generics business.

The Teva Transformation programs are expected to generate approximately $700 million of net savings by 2027. For the 2025 fiscal year, the company is on track to deliver approximately $70 million in net savings from these programs, which is about 20% of the total targeted savings on a full-year run-rate basis. This efficiency gain is a key driver for the reaffirmed target of achieving a 30% operating margin by 2027. We've already seen the impact; the gross profit margin for the United States segment increased to 59.9% in the third quarter of 2025, up from 56.9% in the same quarter of 2024.

Next step: Review the R&D budget allocation to ensure the investment in duvakitug is prioritized, as that $2-5 billion asset is the biggest tech-driven opportunity.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Legal factors

Nationwide Opioid Litigation is Largely Resolved

You're looking for clarity on Teva Pharmaceutical Industries Limited's biggest legal overhang, and the good news is that the nationwide opioid litigation is defintely in the rearview mirror. Teva has successfully resolved its claims with all 50 U.S. states and more than 99% of the litigating subdivisions and special districts. This massive legal complexity is now largely a matter of financial management rather than courtroom drama.

The core of the resolution is a multi-year financial commitment. Teva's total nationwide opioid settlement is for up to $4.25 billion paid out over 13 years. This figure includes a mix of cash and product, specifically the overdose reversal drug naloxone. This structured, long-term payment plan helps smooth the financial impact on the company's balance sheet, which is crucial for a business focused on a 'Pivot to Growth' strategy.

Total Nationwide Opioid Settlement Details

Here's the quick math on what that $4.25 billion settlement actually entails for the company's 2025 fiscal year and beyond. The total value is split between cash payments and the provision of life-saving medicine. This breakdown is key for investors assessing the true cash flow impact.

Settlement Component	Maximum Value	Payment Period
Total Nationwide Opioid Settlement	Up to $4.25 billion	13 years
Cash Payments (to states, subdivisions, tribes)	Up to $3.05 billion	13 years
Generic Naloxone (Overdose Reversal Drug)	Up to $1.2 billion (Wholesale Acquisition Cost)	10 years
Cash in Lieu of Naloxone (Alternative Option)	$240 million (20% of WAC)	As elected by states

What this estimate hides is the ongoing, separate settlements. For example, Teva also agreed to pay up to $126 million in cash over 18 years to U.S. hospitals to settle claims that its opioid marketing increased their operating costs. Plus, they agreed to supply up to $49 million in generic naloxone to these hospitals over seven years. It shows the legal clean-up is comprehensive, but still a significant financial drain.

Ongoing Risk of Intellectual Property and Regulatory Compliance

While the opioid cloud is lifting, Teva, as a global generics and specialty drug powerhouse, faces constant legal pressure from intellectual property (IP) infringement claims and complex global regulatory compliance. This is simply the cost of doing business in pharma.

The biggest near-term risk is the antitrust scrutiny over patent listings. In October 2025, Teva agreed to pay $35 million to settle a class-action antitrust lawsuit alleging improper listing of patents for its ProAir HFA inhaler in the FDA's Orange Book. This followed a December 2024 US Court of Appeals for the Federal Circuit ruling that five of the inhaler's patents were improperly listed because they covered the device, not the active ingredient. Losing this legal shield removes the automatic 30-month stay on generic competition, which is a major strategic blow.

Also, the European Commission fined Teva €462.6 million (approximately $503 million) in October 2024 for misusing the patent system to delay competition for its multiple sclerosis drug Copaxone. This shows global regulators are serious about competition.

The company's own Q2 2025 risk analysis highlights that 'Legal & Regulatory' matters account for 31% of the total risks. This isn't just about lawsuits; it's about navigating a maze of global rules.

• Comply with FDA, EMA, and other regulators on manufacturing and labeling.
• Adhere to new U.S. state pricing laws that impose penalties for high costs.
• Manage global anti-bribery, competition, and economic sanctions laws.

Your clear action is to monitor the cash flow impact of the opioid settlements and, more importantly, track the financial fallout from the IP/antitrust challenges, as these directly impact the time-to-market for generics and the profitability of branded drugs.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Environmental factors

Surpassed the 2025 goal, achieving a 29% reduction in Scope 1 and 2 GHG emissions from 2019 levels.

You need to know where a company is putting its capital to work on environmental, social, and governance (ESG) issues, and Teva Pharmaceutical Industries Limited is showing strong execution on climate. They have already surpassed their near-term goal for operational emissions. The original target was a 25% reduction in absolute Scope 1 and Scope 2 Greenhouse Gas (GHG) emissions-the direct emissions from their owned or controlled sources-by the end of 2025, but they hit this two years early. The latest 2025 fiscal year data confirms they achieved a 29% reduction from the 2019 baseline.

This early win is a strong signal of management focus and operational efficiency. Here's the quick math: they beat the target by 4 percentage points, which defintely lowers their climate-related financial risk profile. They also reduced their Scope 3 emissions (indirect emissions from the value chain) by 12% against a 2020 baseline, tracking toward a 25% reduction goal by 2030.

New long-term target: 100% renewable electricity across all sites by 2035.

The company is mapping out its long-term decarbonization strategy with an aggressive renewable energy goal. Teva has committed to achieving 100% use of renewable electricity across all its global sites by 2035. This is a critical move to future-proof their manufacturing footprint against rising energy costs and carbon taxes. As of their most recent reporting, they were already sourcing 43% of their electricity from renewable sources, showing solid progress toward the 2035 deadline.

This commitment is part of a broader, more ambitious plan to reach net-zero emissions across their entire operations and value chain by 2045. That's a clear action for investors to track over the next two decades.

Issued $7.5 billion in sustainability-linked bonds, the largest in the pharma sector.

A major financial opportunity for Teva is its use of sustainable finance instruments. They have issued a total of $7.5 billion in sustainability-linked bonds (SLBs), which is the largest issuance of its kind in the pharmaceutical sector. This debt instrument is a powerful tool because the interest rate paid on the bonds is tied directly to the company's achievement of its ESG targets.

The total is composed of a $5 billion initial bond in 2021 and a second series valued at $2.49 billion in 2023. The key performance indicators (KPIs) for these bonds include the Scope 1 and 2 GHG emissions reduction and an increase in access to essential medicines. Because they surpassed the GHG reduction target, it's a positive signal for the bond's performance and the cost of capital.

Metric	Target	2025 Fiscal Year Status (as of May 2025 Report)	Financial Linkage
Scope 1 & 2 GHG Emissions Reduction (vs. 2019)	25% by 2025	Achieved 29% reduction (Surpassed target)	KPI for $7.5 billion Sustainability-Linked Bonds
Renewable Electricity Use	100% by 2035	43% used in 2023 (Tracking toward goal)	Part of Net-Zero by 2045 strategy
Antibiotic Safe Discharge Levels	80% of applicable sites	73% of applicable sites achieved safe discharge levels	Reduces Pharmaceuticals in the Environment (PIE) risk

73% of applicable sites achieved safe discharge levels of antibiotics, reducing pollution.

The pharmaceutical industry faces unique environmental challenges, particularly around the discharge of active pharmaceutical ingredients (APIs), like antibiotics, into waterways. Teva is actively managing this risk, which is crucial for public health and regulatory compliance. They have a commitment to minimize antimicrobial discharges to combat Antimicrobial Resistance (AMR).

As of the 2025 fiscal year reporting, 73% of their applicable manufacturing sites achieved safe discharge levels of antibiotics. While this is a high level of performance, it indicates there is still a gap to close against their original target of 80% of applicable sites achieving safe discharge levels (Risk Quotient <1). This is a near-term risk to monitor, as failure to reach the target could trigger regulatory scrutiny or reputational damage, but their current performance is a strong mitigation against environmental pollution.

• Achieved safe discharge at 73% of applicable sites.
• Minimizes environmental pollution from active pharmaceutical ingredients.
• Helps mitigate the global crisis of Antimicrobial Resistance (AMR).

Finance: draft 13-week cash view by Friday.